News

Biosimilars – the view from the US

It’s six years since Europe led the way and created a regulatory framework for approving generic versions of biopharmaceuticals, or biosimilars. Now similar legislation has been enacted in the US

UK returns to the clean energy slow lane

In 2010 global investment in clean energy rose by 30% overall. But in the UK investment plummeted by 70%. Science|Business took the pulse of the UK sector to find out why